Accelerating vaccine development timelines with experience, expertise and automation
Vaccine development is long and intensive process that requires several stages of testing. Multiple assays are required to measure immune responses in candidates to make sure that the vaccine will not elicit robust immune response. In this webinar, our experts will discuss the development of vaccine assays, different types of assays available, specific expertise and tools needed to develop high throughput and robust assays and the support needed for FDA approval. Additionally, they will explore ways to accelerate the timelines for vaccine development.
What will you learn?
- Development of vaccine assays
- Different types of assays available
- Specific expertise and tools needed to develop high throughput and robust assays
- The support needed for FDA approval
Who may this interest?
- Researcher/Developer
- Scientist/Chemist/Analyst
- Director/CEO/VP
- Highest Executive Level
- Lab managers/directors
Speakers
Cyrille Bonhomme, PhD
Director, PPD Laboratory Services, Vaccine Sciences Lab
PPD, Part of Thermo Fisher Scientific (NC, USA)
Cyrille J. Bonhomme, PhD is Director of the PPD Laboratory Services (NC, USA), part of Thermo Fisher Scientifics Vaccine Sciences Lab Department, and oversees the R&D laboratory activities. His academic experience focused on bacterial and viral infectious diseases. The R&D team supports several vaccine programs in various stages of development. He has extensive experience working with clients to move vaccine candidates through the clinical development pipeline, including regulatory submission.
Before joining PPD, Cyrille was a Senior Post Doctoral Fellow at UC Irvine (CA, USA) working on arenaviruses vaccines. Cyrille was responsible for the development of an arenavirus candidate vaccine.
Cyrille received his PhD in Microbiology and Infectious Diseases at the University of the Mediterranean (Marseille, France). His studies focused on developing diagnostics for various rare bacterial diseases.
Liang Zhu
Director of Clinical Biomarker Laboratories
Moderna Therapeutics (MA, USA)
Liang Zhu has a PhD in Analytical Chemistry from National University of Singapore and over 20 years of experience in bioanalytical sciences in academia and the pharmaceutical industry. His expertise is in large molecule bioanalysis, including pharmacokinetic, immunogenicity and biomarker assay strategies, and implementation in a regulated environment. He has a passion for innovation in bioanalysis: optimizing turn-around time on data, improving on the throughput and implementing automation.
At Moderna, Zhu is responsible for building a clinical biomarker laboratory and bringing scientific and technical expertise to support Phase I and-II clinical studies. He is establishing robust clinical sample testing for infectious diseases and therapeutic drug development. His challenges are in creating technical solutions for faster turnaround time without compromising data integrity and quality, the digitization of laboratory processes, and promotion of assay harmonization across the bioanalytical industry.
Professor Petro Terblanche
Managing Director
Afrigen Biologics (Cape Town, South Africa)
Professor Petro Terblanche has a successful track record in the strategic and operational management of technology intensive organizations. She has played a key part in the design and implementation of South Africa’s biotechnology strategy. She holds the position of Managing Director of Afrigen Biologics (Pty) Ltd, which hosts the global mRNA technology vaccine hub under the COVAX initiative. Afrigen also has a mRNA COVID-19 vaccine candidate in development as part of a global program to build capacity and capabilities in low- and middle-income countries to design, develop and produce mRNA vaccines. Petro also holds a part time position as Professor in the Faculty of Health Sciences at the North-West University (South Africa).
A considerable part of her career was in research, development and innovation at the South African Medical Research Council (SAMRC) as well as the Council for Scientific and Industrial Research (CSIR). She has held and is holding several strategic public and private sector board positions in South Africa as well as the position as President of the Stakeholders Organization for the Global Alliance for TB Drug Discovery and Development (2007-2010). She has several qualifications including an MSc and a DSc in Medical Oncology from the University of Pretoria (South Africa). Following this, she was a visiting scientist at Harvard University School of Public Health and thereafter completed a Management of Technology program at Massachusetts Institute of Technology (both MA, USA) in addition to several management and leadership programs from leading institutions globally. Prof Terblanche is the author of more than 200 scientific publications and conference papers in public health. She was recently acknowledged as one of the legends of science by the Academy of Sciences South Africa.
Nick Diamond
Regulatory Lawyer
Jackson Walker (TX, USA)
Nicholas J. Diamond is a Partner at Jackson Walker LLP, based in the firm’s Houston, Texas, office. He maintains a global practice focused on regulatory issues for drug, vaccine, and device companies. He is also an Adjunct Professor of Law at the Georgetown University Law Center (WA, USA) and the University of Houston Law Center (TX, USA).
In association with
